Related Experiment Video
Updated: Jul 11, 2026
06:16
Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
Published on: June 6, 2020
Scottish pharmacists' views and attitudes towards continuing professional development
Ailsa Power1, B Julienne Johnson, H Lesley Diack
1NHS Education for Scotland, 2 Central Quay, 89 Hydepark St., Glasgow G3 8BW, Scotland. ailsa.power@nes.scot.nhs.uk
Pharmacy World & Science : PWS
|September 25, 2007
Summary
Scottish pharmacists
Area of Science:
- Pharmacy Practice
- Professional Development
- Healthcare Education
Background:
- Continuing Professional Development (CPD) is crucial for maintaining pharmacist competency.
- Understanding pharmacists' attitudes towards CPD is essential for optimizing professional growth initiatives.
Purpose of the Study:
- To investigate the views and attitudes of Scottish pharmacists regarding Continuing Professional Development (CPD).
- To identify differences in CPD participation and attitudes across various practice sectors.
Main Methods:
- A postal questionnaire was distributed to a random sample of 2420 Scottish pharmacists.
- Data on CPD activity, motivation, and attitudes were collected and analyzed using statistical tests (t-test, Mann-Whitney test).
Main Results:
- A 22.4% response rate was achieved, with 9.8% of pharmacists reporting no time spent on CPD.
- Primary care and hospital pharmacists spent significantly more time on CPD than community pharmacists.
- Pharmacists in primary care reported higher motivation and attitude scores compared to those in hospital or community practice.
Conclusions:
- A segment of pharmacists remains disengaged from CPD activities.
- Community pharmacists require targeted support to enhance their motivation, confidence, and participation in CPD.
- Primary care pharmacists demonstrate the highest levels of motivation and positive attitudes towards CPD.
Related Concept Videos
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:26Pharmaceutical Poisoning: Potential Scenarios
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...